- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07681934
Swaddling and Breast Milk Odor for Stress and Comfort in Late Preterm Babies Receiving High-Flow Breathing Support Through the Nose
The Effect of the Safe Swaddling Method and the Scent of Breast Milk on Physiological Parameters, Stress, and Comfort Levels in Premature Newborns Receiving Mechanical Ventilator Support: A Randomized Controlled Study
This study compared two approaches to reducing stress and improving comfort in babies born between 34 and 36 completed weeks of pregnancy who were receiving high-flow breathing support through small tubes in the nose.
Seventy-two babies were assigned by chance to one of three groups, with 24 babies in each group. One group was gently swaddled for 20 minutes. A second group was exposed for 20 minutes to the smell of freshly expressed milk from each baby's own mother. The third group received the neonatal intensive care unit's usual care and was observed for 20 minutes.
The study team assessed stress and comfort and recorded heart rate, breathing rate, blood oxygen level, and body temperature at the start of the observation period and again at 5 and 20 minutes. The purpose was to compare how these measures changed over time across the three groups.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Karatay
-
Konya, Karatay, Turquie (Türkiye), 42040
- KTO Karatay University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Gestational age at birth of 34 weeks 0 days to 36 weeks 6 days, inclusive.
- Within the first 28 days of life at enrollment.
- Receiving noninvasive respiratory support via a high-flow nasal cannula (HFNC).
- Birth weight of at least 1,500 g.
- The infant's mother was able to provide expressed breast milk.
- No clinical condition that precluded safe positioning or swaddling.
- Written informed consent obtained from a parent.
Exclusion Criteria:
- A painful procedure within 1 hour before the start of the planned study session.
- Receipt of a medication with analgesic or sedative effects within 6 hours before the start of the planned study session.
- Previous surgery.
- An active or treatment-requiring clinical condition that could affect physiological measurements or the stress response, such as hypoglycemia, hyperbilirubinemia, or acute infection.
- Cerebral hypoxia or ischemia.
- Intraventricular hemorrhage.
- A major congenital anomaly.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Maternal Breast Milk Odor
Infants were exposed for 20 minutes to the odor of freshly expressed breast milk from their own mothers. Ten drops of milk were applied to sterile gauze placed in a sterile container. The container was positioned inside the incubator approximately 1-2 cm from the infant's nose and remained in place throughout the exposure period. |
Ten drops of freshly expressed breast milk from each infant's own mother were applied to sterile gauze in a sterile container. The container was placed inside the incubator near the infant's nose for 20 minutes. |
|
Expérimental: Safe Swaddling
Infants were positioned supine and swaddled for 20 minutes using a thin, breathable muslin cloth measuring 90 × 90 cm. The upper limbs were held alongside the trunk in slight flexion. The lower limbs were left free to allow hip flexion and abduction. The cloth was secured loosely enough to permit chest expansion and spontaneous movement. |
Infants were swaddled in the supine position for 20 minutes using a thin, breathable muslin cloth measuring 90 × 90 cm. The cloth was secured loosely to allow chest expansion and spontaneous movement, and the lower limbs were left free to permit hip flexion and abduction. |
|
Aucune intervention: Standard Care
Infants received the neonatal intensive care unit's standard care during a 20-minute observation period. No additional study intervention was administered. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Newborn Stress Scale Total Score Over Time
Délai: At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Stress was assessed using the Newborn Stress Scale. The scale comprises eight observational domains, each scored from 0 to 2. Total scores range from 0 to 16, with higher scores indicating greater stress. Changes in total scores across the three assessment time points were compared among the study groups. |
At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Premature Infant Comfort Scale Total Score
Délai: At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Comfort was assessed using the Turkish version of the Premature Infant Comfort Scale. Seven indicators are each scored from 1 to 5. Total scores range from 7 to 35, with lower scores indicating greater comfort. |
At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
|
Heart Rate
Délai: At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Heart rate was read directly from the bedside monitor and recorded in beats per minute. |
At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
|
Respiratory Rate
Délai: At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Respiratory rate was read directly from the bedside monitor and recorded in breaths per minute. |
At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
|
Peripheral Oxygen Saturation (SpO₂)
Délai: At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Peripheral oxygen saturation was read directly from the bedside monitor and recorded as a percentage. |
At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
|
Body Temperature
Délai: At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Body temperature was read directly from the bedside monitor and recorded in degrees Celsius (°C). |
At baseline and at 5 and 20 minutes after the start of the assigned intervention or standard-care observation period.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Hediye Karakoç, KTO Karatay Üniversitesi
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- KARATAYU-SBF-ES-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Security
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .